Akamara is a biotechnology company pioneering exciting new types of cancer treatment by developing supramolecular structures that target B-cell immunotherapy. With a lead molecule focused on triple negative breast cancer, Akamara aims to adopt a multidisciplinary approach to research with the ultimate goal of a paradigm shift in cancer care.

Akamara is a biotechnology company pioneering exciting new types of cancer treatment by developing supramolecular structures that target B-cell immunotherapy. With a lead molecule focused on triple negative breast cancer, Akamara aims to adopt a multidisciplinary approach to research with the ultimate goal of a paradigm shift in cancer care.